Jefferies analyst Maury Raycroft maintains $Sangamo Therapeutics (SGMO.US)$ with a buy rating, and maintains the target price at $3.
According to TipRanks data, the analyst has a success rate of 37.4% and a total average return of 5.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following an announcement that its partner will not pursue a Biologics License Application for an investigational gene therapy for treating hemophilia A, a significant asset has reverted back to Sangamo. The company expressed surprise at this turn of events. Despite this, the upside for alternative therapies such as those targeting Fabry disease remains considerable, even under restrained success probability estimations.
The unexpected return of Sangamo's hemophilia A program by a partner, notably close to the planned biologics license application, presents significant challenges. This shift disqualifies Sangamo from receiving $220 million in regulatory and first-sales milestones, thereby increasing its funding pressures. Although Sangamo's current cash reserves are anticipated to fund operations into the first quarter of 2025, the company is exploring partnerships for its Fabry gene therapy program to prolong its financial runway.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富瑞集團分析師Maury Raycroft維持$Sangamo Therapeutics (SGMO.US)$買入評級，維持目標價3美元。
根據TipRanks數據顯示，該分析師近一年總勝率為37.4%，總平均回報率為5.6%。
此外，綜合報道，$Sangamo Therapeutics (SGMO.US)$近期主要分析師觀點如下：
在宣佈其合作伙伴不會追求用於治療血友病A的研究基因治療生物製品許可申請後，一個重要資產已回歸Sangamo。公司對這一事件的發展表示驚訝。儘管如此，針對Fabry病等替代療法的上行潛力仍然相當可觀，即使在限制的成功概率估計下。
合作伙伴意外地撤回Sangamo的血友病A項目，尤其是在計劃的生物製品許可申請臨近時，帶來了重大挑戰。這一變化使Sangamo失去了獲得22000萬美元監管和首次銷售里程碑的資格，進而增加了其資金壓力。雖然預計Sangamo目前的現金儲備可以支持其運營直到2025年第一季度，但公司正在探索其Fabry基因治療項目的合作伙伴關係，以延長其財務週期。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
